Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications

In February 2014, the US Food and Drug Administration (FDA) convened an advisory committee meeting to discuss the accumulated data relating to the cardiovascular risk of non-steroidal anti-inflammatory drugs (NSAIDs) and the potential implications on the class prescription labeling. The committee re...

Descripción completa

Detalles Bibliográficos
Autores principales: Bello, Alfonso E., Holt, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Current Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206767/
https://www.ncbi.nlm.nih.gov/pubmed/25079141
http://dx.doi.org/10.1007/s40264-014-0207-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206767/
https://www.ncbi.nlm.nih.gov/pubmed/25079141
http://dx.doi.org/10.1007/s40264-014-0207-2

Ejemplares similares